Scarica l'app Stockscreener
6.21
0.16%
0.010
Dopo l'orario di chiusura:
6.21
Precedente Chiudi:
$6.20
Aprire:
$6.05
Volume 24 ore:
5,590
Relative Volume:
0.03
Capitalizzazione di mercato:
$3.30M
Reddito:
-
Utile/perdita netta:
$-12.52M
Rapporto P/E:
-0.0514
EPS:
-120.8826
Flusso di cassa netto:
$-4.83M
1 W Prestazione:
+10.30%
1M Prestazione:
-18.50%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.03
$6.40
Intervallo di 1 settimana:
$5.63
$6.70
Portata 52W:
$5.40
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
6.21 | 3.30M | 0 | -12.52M | -4.83M | -120.88 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace
Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com
Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com South Africa
Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com
Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
DCOY Technical Analysis & Stock Price Forecast - Intellectia AI
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz
Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus
Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks
Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - marketscreener.com
Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView — Track All Markets
Decoy Therapeutics (DCOY) restores Nasdaq bid-price compliance after reverse split - Stock Titan
DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView
Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView — Track All Markets
Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Decoy Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):